drugset / Trial / NCT01980589
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
NaSingle-groupOpen-labelTreatment
Summary
The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.
Timeline
- Start
- 2013-08
- Primary completion
- 2016-03
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 20 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |